Logo

Cellular Re-programming utilizing the Immune system​

We use immune cells to deliver therapeutic proteins directly to the cytoplasm of diseased cells to improve patient health.

Cellular Re-programming utilizing the Immune system​

We use immune cells to deliver therapeutic proteins directly to the cytoplasm of diseased cells to improve patient health.

It all starts inside the cell...

1

Roughly two thirds of our body’s proteins are inside cells. These include many key disease pathway targets

2

Existing therapeutic approaches are limited by tissue tropism, toxicity or payload size

3

No currently-available technology can introduce a functional protein into a cell, and very few can target a specific tissue

In nature, immune cells deliver a toxic payload to eliminate diseased cells

Immune cells are capable of active deep tissue penetration and intracellular protein delivery and are free of toxicity concerns.

WE REDESIGN IMMUNE CELLS TO DELIVER PROTEIN THERAPEUTICS INSTEAD

This opens up a new universe of targets for treatment that have not previously been translated to the clinic.

Edity’s technology integrates therapeutic proteins into the perforin-granzyme pathway, delivering directly to the cytosol of target cells.

Sophisticated protein design and highly efficient transformation protocols ensure superior protein expression and transferability

Plug And Play Technology

Builds on clinical grade technologies

  • Compatible with allogeneic approaches.

  • Shown to work with T-cells, NK cells.

  • Edity’s technology can use CAR, TCR or similar modalities for homing and activation.

Plug And Play Technology

Builds on clinical grade technologies

Compatible with allogeneic approaches.

Shown to work with T-cells, NK cells.

Edity’s Technology can use CAR, TCR
or similar modalities for homing
and activation.

Creating new modalities
for intracellular therapy

We deliver proteins to cells anywhere in the body

Creating new modalities
for intracellular therapy

We deliver proteins to cells anywhere in the body

ABOUT US

Edity is developing an exciting new platform that harnesses the immune system to deliver therapeutic proteins direct to the cytoplasm of target cells to reprogram cells and tissue back to health.

The technology creates the opportunity to change the course of disease at the intracellular level via multiple mechanisms including protein replacement, target modulation, genetic correction and protein gain of function.  Currently, the company is working across a number of indications, including oncology and genetic disease, while developing programs for regeneration and longevity.

VISION

We dare to dream & manifest new therapeutic paradigms offering hope for patients by transforming the immune response to reprogram cells from the inside out

MISSION​

Edity is expanding the use of immune cells for cellular reprograming for better health

VALUES

EMPOWERING

Every voice is heard

PRODUCTIVE

Curiosity creating excellence

COURAGE

We dare to the unknown

RESILIENCE

Striving & Achieving

WE CARE​

Our People

Eyal is a serial entrepreneur and has devoted the majority of his career to building medical device companies. He founded TopSpin medical, Pi-Cardia and Clear-Cut.

Eyal Kolka​

CO-FOUNDER, CHAIRMAN OF THE BOARD​

Michal is graduate of the Weizmann Institute of Science and a seasoned expert in gene editing and genetic screening, having spent four years at Emendo before going onto found her own company, Applied Genetics. Michal founded Edity in 2020.

Michal Golan-Mashiach
PhD, MBA

CO-FOUNDER AND CEO

Abigail is a veteran biotech executive. She has global experience leading corporate strategy, business development and operations across several early-stage companies, with expertise in cell therapies.

Abigail Bracha

PRESIDENT

Ofer is an expert in tumor immunology and has gained a strong industrial experience in Compugen focusing on target validation of immuno-oncology programmes.

Ofer Levy, PhD

VP R&D

Sharon is an experienced biochemist and renowned oligo nucleotides expert. At QBI, she headed the entire planning of pre-clinical studies the pre-clinical siRNA pipeline, including in vitro and in vivo trials.

Sharon Avkin Nachum, PhD​

VP TECHNOLOGY 

Assaf is an expert in CAR-T science and has had positions at the Weizmann Institute, UC Berkely and AbbVie. He is an inventor on one of the first allogeneic CAR T cell patents.

Assaf Marcus, PhD

VP TRANSLATIONAL SCIENCE

Advisors

Sandra is a seasoned biotech executive and serial entrepreneur with 30 years of company building across multiple therapeutics modalities. Formerly served as founder and COO at Editas Medicine, Inc

Sandra Glucksmann

Board Member

Richard ‘Rick’ Kendall has more than 30 years of experience in biotechnology and the biopharmaceutical industry including executive positions at Kite Pharma and Amgen. Most recently he served as CEO at ImmPACT-Bio USA Inc.

Rick Kendall

ImmPACT-Bio USA Inc.

Reuben S. Carpentier Professor,
Columbia University.
An international leader in the immunobiology of human NK cells

Jordan S. Orange

Columbia University

American Cancer Society Professor and Chair of the department of Microbiology and Immunology, UCSF. An Internationally-recognized expert in natural (NK) cells.

Lewis Lanier

UCSF

Professor Yoram Reiter from the Technion institute of technology is a world leader in immunotherapy. His research is focused on targeting the intracellular proteome, T cell biology and CAR-T cell engineering

Yoram Reiter

Technion

Investors

Publications

Publications

Contact us

+972-54-7414417
info@edity-tx.com
10 Menachem Plaut St.
7670609, Rehovot, IL
Linkedin